NCT01761227View on ClinicalTrials.gov

Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Vascular Dementia
Interventions
DRUG

Fufangdanshen Tablets

1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks

DRUG

Placebo

Placebo for 3 tablets per time, 3 times per day for 24 weeks

Trial Locations (1)

100700

Dongzhimen Hospital ,Beijing University of Chinese Medicine, Beijing

All Listed Sponsors
collaborator

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited

INDUSTRY

lead

Dongzhimen Hospital, Beijing

OTHER

NCT01761227 - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia | Biotech Hunter | Biotech Hunter